BioGenes
Latest round
- Series B
Last raised
- Jan 2004
Total raised
- Undisclosed
Investors
- 2
About BioGenes
Founded in Berlin, Germany, BioGenes GmbH focuses on custom antibody solutions and immunoassays. Under the leadership of CEO Alexander Knoll, the company has maintained a consistent operational strategy without notable pivots.BioGenes specializes in the development of custom antibody solutions and immunoassay services tailored for both industry and research applications. Their core offerings include bespoke monoclonal and polyclonal antibodies, custom immunoassays, and host cell protein (HCP) monitoring products. These services are integral to various phases of drug manufacturing, particularly in addressing HCP impurities that can affect drug efficacy and safety. BioGenes has established a diverse client base, including pharmaceutical companies and research institutions across more than 40 countries, indicating a robust global market presence.BioGenes operates on a B2B model, providing tailored services to pharmaceutical and biotechnology firms which require high-quality custom antibodies and immunoassays for their research and development efforts. The revenue structure is primarily based on project-based contracts, where clients engage BioGenes for specific services, such as the development of tailored HCP ELISA assays or antibody production. Each project is customized, allowing clients the flexibility to choose single services or complete packages, which may include consulting, assay development, and analytical testing. Detailed pricing structures are aligned with the complexity and scope of services offered, ensuring competitive and transparent pricing for their flagship products and services.BioGenes GmbH plans to enhance its product offerings with new custom antibody solutions expected to launch in the coming years. The company aims to expand its market presence into new regions, specifically targeting the North American and Asia-Pacific markets by 2025.
Who invested in BioGenes
2 investors across 1 round
See all investors in BioGenes
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 12, 2004
Amount
Undisclosed
Investors
Questions about BioGenes
Who invested in BioGenes?
BioGenes has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioGenes raised?
BioGenes has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BioGenes last raise money?
BioGenes's most recent round on record is a Series B, in Jan 2004.
What does BioGenes do?
Founded in Berlin, Germany, BioGenes GmbH focuses on custom antibody solutions and immunoassays.
Where is BioGenes headquartered?
BioGenes is headquartered in Berlin, Germany.
Which VCs invest in companies like BioGenes?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at BioGenes's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BioGenes? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.